Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price

Kezar Life Sciences (NASDAQ:KZR) had its price target cut by equities researchers at Wells Fargo & Company from $20.00 to $11.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 46.67% from the company’s previous close.

Several other research analysts have also recently commented on the company. HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, October 14th. William Blair restated a “market perform” rating on shares of Kezar Life Sciences in a research note on Wednesday.

Kezar Life Sciences Trading Down 0.5 %

KZR stock traded down $0.04 during midday trading on Thursday, hitting $7.50. 661 shares of the company’s stock were exchanged, compared to its average volume of 73,845. Kezar Life Sciences has a one year low of $5.20 and a one year high of $11.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 9.58. The company has a market cap of $54.72 million, a PE ratio of -0.57 and a beta of 0.22. The stock’s fifty day moving average price is $7.13 and its 200-day moving average price is $6.84.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($2.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.20) by $0.40. Research analysts predict that Kezar Life Sciences will post -11.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kezar Life Sciences

A number of hedge funds have recently bought and sold shares of KZR. Affinity Asset Advisors LLC bought a new position in Kezar Life Sciences during the 1st quarter worth $1,588,000. Stonepine Capital Management LLC bought a new stake in Kezar Life Sciences during the second quarter worth about $630,000. Acadian Asset Management LLC grew its stake in Kezar Life Sciences by 42.5% during the first quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock worth $1,613,000 after buying an additional 534,203 shares in the last quarter. Acuitas Investments LLC increased its holdings in Kezar Life Sciences by 42.8% in the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after buying an additional 295,956 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Kezar Life Sciences in the 2nd quarter valued at approximately $63,000. 67.90% of the stock is owned by institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.